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Summary.-Ten xenograft lines of human colonic and rectal carcinomas have been
established in immune-suppressed mice. Mice bearing tumours in the 2nd to 6th
passage were treated with maximum tolerated doses of 8 chemotherapeutic agents
and tumour growth delay was estimated in terms of the number of volume doubling
times gained by the treatment. The average response corresponded to a delay of only
about 0-5 doubling times, but some tumour lines showed a good response to some
agents. Twenty-three out of about 700 treated tumours failed to regrow. Statistical
analysis showed no consistent difference in sensitivity among the tumour lines, but
melphalan, 5-fluorouracil and hexamethylmelamine stood out as the most effective
agents. A study of two-drug combinations showed that their order of administration
had little effect on response. Only 4 of the patients who donated the xenografts were
treated with chemotherapy, but among these there was some evidence that response
in the xenografts correlated with response in the patient.
A QUESTION that is central to the
chemotherapy of cancer is to what extent
the patients within one particular histo-
pathological disease category differ in
regard to the sensitivity of their tumour
cells to cytotoxic agents. Attempts have
been made to test the chemosensitivity of
tumour cells from individual patients,
using tissue culture techniques (e.g. Berry
et al., 1975) but the artificiality of the
conditions ofexposure and ofthe biological
end-points has meant that the extent of
variation in response has been particularly
difficult to assess. As part of a wider
programme of research into the thera-
peutic response of human tumour xeno-
grafts, we have attempted to measure the
range of responses among a group of 10
different lines of colo-rectal carcinoma
(numbered HXK -10), and where possible
we have sought to correlate the results
with the clinical response of the patients
from whom the grafts were taken. This
paper describes the results of this study,
with emphasis on the assessment of inter-
patient and inter-drug variations.
MATERIALS AND METHODS
Tumnour material.-The tumour tissues used
in this study were operative specimens taken
from patients with adenocarcinoma of the
colon or rectum (Table I). One of the authors
(K.N.) personally attended surgery in every
case, and examined the tumours in situ
together with the attending surgeon. Follow-
ing resection of the tumour, the specimen
was washed in sterile saline and a wedge-
shaped sample of the growth was taken,
including the invading edge. Wherever
possible, specimens of liver metastases and
involved lymph nodes wrere also taken. They
were transported to the laboratory in ice-
cold tissue-culture medium containing anti-
biotics (Eagle's basal medium (BME) plus
penicillin 0-25 g/l, streptomycin 0 05 g/l,
neomycin 0-1 g/l). Fragments measuring
2 mm across w-ere dissected from the most
* Present ad(lress: Department of Surgery, St George's Hospital, Tooting, London SW17 OQ.J. This work
forms part of an M. Phil. thesis submitted by K.N. to the University of Lon(doln.
t Communications regarding this paper should be directedl to Dr Steel.CHEMOTHERAPY OF XENOGRAFTS
TABLE I.-Source of Tumour Material
Patient
Designation Sex Age
HXK1* F 57
HXK2
HXK3
HXK4
HXK5
HXK6
HXK7
HXK8
HXK9
HXK1O
M
M
F
F
M
M
F
F
M
92
70
59
73
69
71
52
50
38
Diagnosis
Ca caecum Duke C
Ca sigmoid Duke C
Ca caecum Duke C
Ca rectosigmoid Duke C
Ca caecum Duke C
Ca rectum Duke B
Ca rectum Dike C
Ca sigmoid Duke B
Ca caecum Duke C
Ca transverse colon Duke C
Histological type of adenocarcinoma
Differentiation Other features
Moderate Mucus-secreting in
areas, liver in-
volvement
Moderate Liver involvement
Moderate Liver involvement
Moderate Mucus-secreting
Poor
Moderate
Moderate to poor
Moderate
Poor
Moderate Mucus-secreting
* For the sake of clarity, the initial letters HX are omitted from the textual references of these tumours.
viable part of the tumour specimen and
implanted s.c. into recipient mice within 2 h
of removal from the patient.
Immune-deprived mice.-Male and female
CBA/lac mice were used, produced in the
Institute of Cancer Research breeding sta-
tion. At 3-4 weeks of age they were thy-
mectomized, and 2 weeks later they were
given a dose of 9 gray whole-body irradiation
from a 60Co source, using a dose rate of about
0-65 gray/min. Within 2-4 h the mice received
an i.v. injection of 5 x 106 syngeneic marrow
cells to restore haemopoiesis. The mice were
kept under non-sterile conditions in a con-
ventional animal house, though separated
from rooms containing mice used for non-
xenograft work.
Tumour transplantation and measurement.-
Tumour specimens were placed in chilled
BME containing antibiotics, and initially
cleared of necrotic tissue and fat. Pieces
measuring 8 mm3 were then removed using
sharp scalpels, so as far as possible to preserve
uncrushed edges. The pieces used for trans-
plantation were then picked at random and
implanted s.c. over the posterior rib cage on
both sides of the animal. The implants were
inserted with a pair of forceps into deep
subcutaneous pockets and each wound closed
with a single metal clip. The mice were
observed for signs of tumour growth, and
shaved to allow the implants to be measured
accurately. Further transplantation was
carried out from tumours that had reached a
volume of -2 cm3.
Growing tumours were measured every
2-3 days using plastic calipers graduated to
0-1 mm. The largest and smallest superficial
dimensions were recorded, and tumour
volume was calculated as n/6 (mean
diameter)3. Groups of tumours were selected
for chemotherapy when their average volume
was 0-.0-2-0*5 cm3. Volume measurements
were continued, and the interval during which
each tumour increased to twice its volume
at the time of treatment was found by inter-
polation on a semi-logarithmic plot. For each
group of treated or control tumours, the
median time to double (TD) was calculated
and the growth delay that resulted from each
treatment was defined as
Growth delay=TDtreated-TDcontrol
TDcontrol
This quantity may be regarded as an estimate
ofthenumber ofvolume doubling times saved
by the treatment. By calculating in this way,
one arrives at a quantity that should allow
comparisons to be made between tumours
that have different rates ofuntreated growth.
Chemotherapy.-Table II lists the 8 chemo-
therapeutic agents used in this study. The
decision to use 4 agents in single dose and
4 as 5 daily doses was based on the clinical
protocols in use in the Royal Marsden Hospi-
tal and, in the case ofHMM and cis-platinum,
on the advice of our colleagues who are using
these new agents. The dose levels were
selected on the basis of toxicity studies. We
attempted to use the LD10 level, but because
of the notorious variability in maximum-
tolerated dose from one experiment to
another there was considerable variation in
the deaths due to our chosen drug levels.
Two series of combination studies were
performed, using 5FU and MeCCNU, and
actinomycin D and melphalan. In each case
the combination was more toxic than the
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TABLE II.-Chemotherapeutic Agents and Dosage
Manufacturer
Roche Products Ltd.
Division of Cancer Treat-
ment, NCI. NSC 95441
Burroughs Wellcome Co.
Merck, Sharp & Dohme
Chester Beatty Research
Institute
Lederle Laboratories
W. B. Pharmaceuticals Ltd.
Cis-dichlorodiamino-platinum (Pt) Chester Beatty Research
Institute
* All given i.p.
drugs used alone. On the basis of toxicity
studies, the drug doses were reduced as
follows: MeCCNU to 25 mg/kg when given
during or after the 5FU course, and to 20 mg/
kg when given before the 5FU; the 5FU dose
. - 1. 1.... was not reduced. Melphalan
8 mg/kg, and actinomycin I
C'.)
t..
0
groups i u mou slU uinere w abrai oi
growth rates and, bearing in mind that
this study involved the measurement of
over 700 individual treated tumours, it is
impossible to present the detailed results
on each ofthem. The Fig. is an example of
the data that were obtained. From plots
of this type the individual time to double
(TD) was measured and the median TD
of each treated group was determined.
The reason for choosing the median TD
was that some tumours failed to regrow
20 40
Days after in
FIG. Example of a set of grov
control tumours (top) and trE
(bottom). Arrows indicate tri
example presents the data fc
treated with 5FU alone.
during the course of the experiment, and
their individual TD values were therefore
indefinitely large. The view will be
developed below that these failures to
regrow probably indicate the combination
of a relatively good anti-tumour effect
onthe part ofthe agent, with aconsiderable
degree of help from host factors. If this
view is correct, we should not give the
failures to regrow undue weioht but to
60 80 exclude these tumours would bias the
nplantation results against tumour lines that showed
vth curves for failures to regrow. In this situation it
eated tumours would seem best to work in terms of
eatment. This median values. Growth delay (as defined
:)r the K4 line
above) was calculated using for reference
Preparation Dosage*
Aqueous solution 30 mg/kg qd x 5
In dimethylsulphoxide 30 mg/kg single
and 5% Tween 80 dose
in saline
Ethyl alcohol acidi- 12 mg/kg single
fied and propylene dose
glycol in water
Aqueous solution 0-5 mg/kg single
Suspension in
arachis oil
Aqueous solution
Aqueous solution
Aqueous solution
dose
5 mg/kg qd x 5
5 mg/kg qd x 5
200 mg/kg
single dose
3 mg/kg qd x 5
when given aftermelphalan and to 0 35 mg/kg
when given before melphalan.
RESULTS
Agent
5-Fluorouracil (5FU)
MeCCNU
Melphalan (Melph)
Actinomycin D (Act D)
Hexamethylmelamine (HMM)
Methotrexate (MTX)
Cyclophosphamide (CY)
was reduced to Growth delay in the xenografts
) to 0-25 mg/kg Within both the treated and untreated
er"vul"C r%- +kav., -hnXlTrC o T-Qfrn r%
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TABLE III.-Proportion of
Positive Takes
Xeno- Pas-
graft sage
KI II
III
IV
V
K2 II
III
IV
V
VI
K3 II
III
IV
K4 II
IV
K5 II
III
K6 II
III
K7 II
III
K8 II
III
K9 II
III
K1O II
TD* Animals
(days) grafted
13 22
15 41
14-5 24
34
18-5 60
14 13
14 25
24
10
19 22
16-5 30
36 25
13 50
12-5 24
9 59
10 16
13 40
9.5 16
16 47
14-5 20
10-5 47
28
11 48
18
21-5 48
* Median volume-doubling
controls.
Propor-
tion of
mice
No. develop-
with tu- ing
mour(s) tumour(s)
16
20 0-82
28
49
13
16 0-78
19
6
12
14 0 44
8
39 0-82
22
53 0-89
14
34 0 86
14
47 0 97
18
33 0-53
7
31 0-58
6
40 0-83
time of untreated
the TD of untreated control tumours
implanted at the same time. These TD
values are summarized in Table III,
together with the proportion of mice
grafted with bilateral tumours in which at
least one tumour was available for
chemotherapeutic investigation. These
take-rates per mouse were generally in
excess of 50%, but only K7 came close to
100%.
The median growth delays calculated
for each group of treated tumours are
summarized in Tables IV, V and VI, and
Table VII shows the incidence of failures
to regrow amongst the various tumour-
drug combinations.
Analysis of the xenograft response to single
agents
Table IV includes growth-delay data
for each of the 10 tumour lines challenged
with up to 8 single agents. Many of the
values are small, but values exceeding 1-0
doubling times indicate a considerable*
growth delay, and are given in heavy
type. It can be seen that in spite of only
14/64 median growth delays exceeding
1-0, this level of response was achieved at
least once with every tumour line, and
every drug except cyclophosphamide and
cis-platinum achieved this level in at least
one tumour line. This simple observation
therefore points to the fact that good
responses were widely scattered, both
among the drugs and among the tumour
lines.
The questions that one would hope to
answer on the basis of the data given in
Table IV are:
(i) Can we say that some tumours
showed significantly different re-
sponse from others?
(ii) What is the ranking of the drugs
against these tumours, and are their
differences in effectiveness statisti-
cally significant?
(iii) Is there evidence for particular
tumours showing strong response to
particular agents?
The first two of these questions suggest
an analysis of variance among the drugs
and the tumour lines, and in this situation
it is appropriate to use a non-parametric
method. We have therefore employed
Friedman's two-way analysis of variance
by ranks (Siegel, 1956) using median
growth delay as the response parameter.
The results are shown in Tables VIII and
IX. Since some tumour-drug combinations
were not studied, this test was applied to
7 drugs and 8 tumour lines.
When the tumour lines are ranked
against the drugs (Table VIII) the
probability that the sets ofranks occurred
by chance on the null hypothesis of no
difference among the tumour lines is
0 4. The inter-tumour differences in the
ranks are therefore not significant and we
must conclude that the tumour lines
* The coefficient of variation of the control TDs was always in the range 0-25-0-35.
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TABLE IV.-Response* of Tumour Xenograft Lines to Single Agents
Drug
A
MeCCNTJ Melph
>5 2-5
0-6 1-0
0-6
0 0-3
0-4 0-7
0-4 0-8
0-1 1-1
0-5 1-8
0-1 (3)
0-9 0-5
Act D
0*5
0
(0*5)
0-5
2-7
0-1
0-1
0-5
0-6
0.1
HMM
0*9
0-8
1*5
0 5
1-4
1-2
MTX
0-2
0
CY
0
0-1
0-1 0-2
2-9 0-6
0-7 0-5
0-2 0-4
Grand
median
growth
Pt delay
0-7 0-9
(0) 0-2
0-4
0 0- 7
0-6
0-5 0-4
0-5 0-1 0-1 0-3 0-4
0-8 0-3 (4-5) 0-4
delay 0-5 0-4 1-0 0-2 0-8 0-2 0-3
* The figures indicate the median growth delay of each batch of treated tumours. Values in brackets are
uncertain, being based on too few tumours. Values in heavy type, growth delays of 1-0 or more.
did not show significant differences in
response to all the agents. When, however,
the drugs are ranked against the tumours
(Table IX) the differences are just signi-
ficant at the 0-05 level. There is therefore
some evidence that the drugs varied in
TABLE V.-Response* of Tumour Xeno-
graft Lines to Drug Combinations
Combination of 5FU
and MeCCNIJt
Combination
of Melphalan
and Act D:
Tumour 5FU To- 5FU Melph Melph
line first gether second first second
K1 >9 >7 >6 3-0
K2 0-7 0-5 0-4 (1-8) 0-3
K3 2 2-5 1-2 1-0
K4 0-4 1-3 0-7 0-1 0-4
K5 2-2 >9 0-5 (3) 0-7
K6 0-4 1-5 0-4 0-1 0-3
K7 1-0 1-1 1-3 1-0 1-2
K8 1-2 1-5 1-5 1.1 0-8
K9 0-9 0-7 1-8 1-1 0-5
K10 0-5 0-4 (1) 0 - 6 1-8
Grand
median
growth
delay 1-0 1-4 1-2 1-0 0-8
* The figures indicate the median growth delay
of each batch of treated tumours. Values in heavy
type, growth delays of 1-0 or more.
t 5FUgivenin 5 daily doses. MeCCNUgiven 5 days
before the first, with the third, or 5 days after the
fifth dose. MeCCNU dose was reduced from 25 mg/kg
to 20 mg/kg when given before 5FIJ.
t Melphalan was followed by Act D (0-25 mg/kg)
at 1 day; Act D (0-35 mg/kg) was followed by
Melphalan at 1 h.
TABLE VI.Response* of Tumour Xeno-
graft Lines to Combinations ofMelphalan
and Act D
Tumour line
K1
K2
K3
K4
K5
K6
K7
K8
K9
K10
Grand median
growth delay
Combination
K A
Melph-+Act Dt ActD-+Melpht
3-0
(1-8) 0-3
1-0
0-1 0-4
(3) 0 7
0-1 0 3
1-0 1-2
1.1 0-8
1-1 0-5
0-6 1-8
1-0 0-8
* The figures indicate the median growth delay of
each batch oftreated tumours. Values in heavy type,
growth delays of 1-0 or more.
t Melphalan was followed by Act D (0-25 mg/kg)
at 1 day.
t Act D (0-35 mg/kg) was followed by melphalan
at h.
their effectiveness against all the tumour
lines. Inspection of the rank totals shows
that the scores for melphalan, HMM and
5FU were considerably lower than for the
other 4 drugs, and therefore there are
grounds for concluding that these 3
agents were significantly more effective
than the others. These were the 3 agents
that also rank best in terms ofthe number
oftumour lines that gave agrowth delay in
excess of 1-0 (Table IV).
Tumour
line
KI
K2
K3
K4
K5
K6
K7
K8
K9
K1O
Grand
median
growth
5FIJ
1-4
0-2
1-7
0-5
>9
0-6
0-4
1*9
0-5
0-3
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TABLE VII.-Incidence of Tumours That Failed to Regrow*
Drug
Tumour line 5FU
Kl
K2 2/8
K3 1/9
K4
K5 4/6
K6
K7
K8
K9
KIO
Total failures to regrow 7
MeCCNU Melph Act D HMM
5/9 1/4
2/8
2/6 1/6
MTX CY
1/5
2/6
2/4
7 7 0
Total
failures
---s to
Pt regrow
6
2
1
3
7
0
2
0
2
0
0 0 23
* Tumours that failed to return to treatment size within the duration ofthe experiment (2 months or more)
as a fraction of the number of tumours whose size was followed.
TABLE VIII.-Statistical Analysis* ofTumour Ranking
5FU MeCCNU Ml
2
8
4-5
1
3
6
1
3
8
4-5
4-5
6-5
4-5 6-5
7 2
.elph Act D H^MM MTX CY Rank total
1 4 4 4-5 8 24-5
4 8 5-5 8 6-5 43
8
6
5
3
3
1
7
6
1
7.5
2
3
6-5
1
2
4-5
5
2
3
4
36
23
26-5
33
2 2 7-5 6-5 6-5 35-5
7 5 5.5 3 1 30 5
x2=7-6 (7 d.f.). P=0.4.
* By the Friedman 2-way analysis of variance by ranks (Siegel, 1956). Low ranks indicate good response.
TABLE IX.-Statistical Analysis* of Drug Ranking
5FU MeCCNU Melph
3 1 2
4 3 1
2-5 7
1
4
3 -5
3 -5 5.5
27
Act D HMM
5 4
6-5 2
4 2-5
4 3
2 7
2 6 5
7
6
6-5
6
2
38-5
1
4
20
2
7
39.5
1
6
1
1
3-5 6
3
21 -5
MTX
6 7
6-5 5
6
2
3
5
5S5
40
x2= 12-6 (6 d.f.).
P=0.05.
* By the Friedman 2-way analysis of variance by ranks (Siegel, 1956). Low ranks indicate good response.
Although there does appear to be ofdrugs, there was evidence for the specific
evidence for significant differences in drug sensitivity of a given tumour to one or
effectiveness, it should not be overlooked more particular drugs.
that the less effective agents did give good
responses with some tumour lines (Table Analysis of the xenograft response to drug
IV). The data therefore support the view combinations
that, over and above the broad ranking The studies of drug combinations were
KI
K2
K3
K4
K5
K6
K7
K8
K9
K10
KI
K2
K3
K4
K5
K6
K7
K8
K9
K1O
Rank total
CY
5
5
5
3-5
6
1
37 -5
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broadly disappointing. The choice of 2
pairs of drugs (5FU and MeCCNU;
melphalan and actinomycin D) was made
at the start of the investigation, before
the single-agent ranking was known. In
the event, each of these combinations
included one high-ranking drug and one
that ranked poorly. The objective of the
combination studies was not to show that
the combinations could give a greater
tumour growth delay than single agents
(to show this would require proof that the
combination and single-agent treatments
were equitoxic). The objective was to
study the effect of timing in the drug
combinations. It is from this point ofview
that the results are disappointing: the
study has probably failed to identify an
optimum drug timing. As shown in Tables
V and VI, each combination gave a good
proportion of responses in excess of 1-0
doubling times. In KI and K5 treated
with 5FU and melphalan, there were
treatment groups in which more than
half the tumours failed to regrowduring
the course of the experiment. In these
groups it is not possible to obtain the
median growth delay, so a minimum
value is given instead. It can be seen that
these median values show no obvious
trend in favour of one combination over
another and the grand median values for
each combination against all the tumour
lines are similar.
Clinical response of the patients
Ofthe 10 patients from whom xenograft
lines were established, 4 were treated
with cytotoxic drugs but subsequently
died. The remaining 6 received no treat-
ment other than surgery and 2 of these
patients are alive and well. The patients
who received chemotherapy were the
donors of xenografts KI, K3, K9 and
Kio.
K1 patient
During an operation for right hemi-
colectomy the liver of this patient was
found to contain multiple metastases. On
abdominal examination, the edge of the
liver could be palpated below the right
costal margin, and ultrasonography con-
firmedthe presenceof multiplelesions. The
serum carcinoembryonic antigen (CEA)
level was elevated (62 ng/ml). The course
of treatment consisted of MeCCNU
(150 mg/M2 on Day 1), 5FU (325 mg/M2
i.v. daily for 5 consecutive doses), and imi-
dazolecarboxamide (75 mg/M2i.v. dailyfor
5 consecutive doses). Eight courses of
treatment were given over a period of
11 months.
About 2 months after the start of
treatment, the condition of the patient
improved, she began to gain weight and
the serum CEA level fell. The liver was no
longer palpable and the ultrasound scan
showed no progression of the disease. In
spite of continued treatment, 5 months
later the patient's condition deteriorated
and she died, having survived 14 months
from diagnosis.
K3 patient
This patient had a palliative right
hemicolectomy. The liver was enlarged
and multiple liver metastases were found;
the serum CEA level was 480 ng/ml. This
patient received 4 courses ofchemotherapy
(as for patient K1) but this was dis-
continued when it became evident that he
was not responding. The survival time
from diagnosis was 13 months.
K9 and K1O patients
Both these patients had rapidly pro-
gressing disease. There was no evidence of
response to chemotherapy and they died
having received only one and 3 courses of
treatment respectively.
DISCUSSION
General conclusions on the ranking of the
anti-tumour agents
The statistical test that is summarized
in Table IX has shown that, when the
drugs are ranked in terms of the response
achieved with all the 8 tumour lines that
could be assessed, the differences in
response were just significant at the 0.05
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level. Melphalan, 5FU and HMM stood
out as being the most effective agents.
However, inspection ofthe median growth
delays shown in Table IV shows that
differences among the drugs were not
large, and that good responses (defined
as growth delays > 10 volume-
doubling time) were scattered among
almost all the drugs and tumour lines.
Although it would take multiple repeats
of the experiments to confirm that these
good responses did not occur by chance,
the results suggest that each tumour line
had its own spectrum of drug response,
and that the drug giving a good response
was not always the same. For instance,
actinomycin D and MTX, although they
ranked poorest overall, nevertheless
achieved a very good response in K5. The
data therefore support the policy of
seeking to develop valid laboratory tech-
niques by which a patient's tumour cells
may be tested against a range of single
agents in order to decide upon the best
treatment for the individual case.
In the drug-combination experiments,
we have not been able to show that the
time of administration of MeCCNU in
relation to a 5-day course of 5FU was
important, or that the order ofadministra-
tion of melphalan and actinomycin D was
important. Evidence that 5FU given after
CCNU is less effective than when given
with or before CCNU to the Lewis lung
tumour has been reported by Mulder et al.
(1977). It is, however, difficult to judge to
what extent this was so because when
5FU was given second it was given on Day
4 after implantation, as compared with
Day 2 or 3 for the other groups.
Evidence for the influence of host resistance
on tumour response
In the previous study in this laboratory
by Kopper and Steel (1975), two observa-
tions pointed towards the existence of
significant host reaction against human
tumour xenografts. When bilateral s.c.
implants were made, the incidence of
single takes per mouse was well below the
level that would have been expected on
the basis of a binomial distribution (i.e.
the takes were not random) and the most
likely conclusion was that the mice
differed in regard to degree of immune
suppression, some mice being well-sup-
pressed (and tending to give double takes)
and some mice being poorly-suppressed
(and tending to give zero takes). The
second line of evidence came from xeno-
grafts of a small-cell carcinoma of the
bronchus treated with single doses of
cyclophosphamide. At doses approaching
the maximum tolerated levels, long-term
tumour control was achieved in about
half the tumours that were treated. At the
same time, tumours that were not cured
at the same doses showed only a modest
growth delay, consistent with treatment
having reduced the number of viable
tumour cells by a factor of /10-100. This
surprising therapeutic response is consist-
ent with the existence of a strong host
response against the tumour which, when
treatment had reduced the number of
tumour cells from about 108 to 107 or
106, could suppress the regrowth of the
residue.
The data obtained in the present series
of experiments on colorectal carcinomas
have features in common with this earlier
work. As shown in Table VII, there were
altogether 23 tumour implants that failed
to regrow to the treatment size within the
duration ofthe experiment. These occurred
in 7 ofthe 10 tumour lines, but the bulk of
the failures to regrow occurred in response
to 5FU, MeCCNU and melphalan. These
''cures" occurred amongst a group of
tumours whose overall median growth
delay was 0 51 doubling times. Although
it is dangerous to try to infer the level of
clonogenic-cell kill from an average growth
delay (McNally, 1973; Steel and Adams,
1975), it is difficult to believe that a 0-5
doubling time growth delay was associated
with as much as 9000 cell kill in most of
the tumours.
During the course of these experiments,
parallel work in this laboratory has
identified ways of improving the level of
immune suppression of thymectomized
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mice (Steel et al., 1978) and by means of
cell titration tests it has been shown that
mice thus suppressed may be more
receptive to transplantation than congeni-
tally athymic (nude) mice. Whilst con-
firming the importance of host resistance
against xenografts, this work indicates
that it can be manipulated.
Relationship between the response of the
xenografts and the clinical response of the
patients
The comparison of the response of the
xenografts and the response ofthe patients
to chemotherapy was one objective of the
present work, but the results are inconclu-
sive. Colorectal carcinomas were selected
because of the likelihood that 8 or more
tumour lines might be established within
aperiod ofabout 12 months. We were fully
aware that not all the patients would
eventually be given chemotherapy, and
that assessment of response would be
difficult. In the event, only 4 patients
received chemotherapy. One responded
well, while the other 3 did not respond to
drug treatment. Theirtreatment wasbased
upon 5FU and MeCCNU, and it is signifi-
cant that the xenografts from the patient
who did well (Ki) ranked highest ofall the
tumours against MeCCNU and ranked
second highest against 5FU. Furthermore,
in the tests of combinations of 5FU and
MeCCNU (Table V), KI was the most
responsive ofthe 10tumourlinesexamined.
Although it is disappointing that in only
1 of these 10 cases could the patient's
response to chemotherapy be objectively
assessed, it is nevertheless remarkable
that her clinical response was good in
comparison with other colonic carcinoma
patients treated on this schedule, and
that the response ofher tumour xenografts
was the best of the 10 lines that we have
studied.
Carcinoma of the colon and rectum is a
disease that does not respond well to
existing chemotherapy. The xenograft
responses are broadly in line with this,
with an average overall growth delay of
less than one volume-doubling time.
Perhaps the most important result of the
present study is the evidence that indivi-
dual tumour lines responded best to
different agents, thus supporting the need
to develop tests of tumour-cell chemo-
sensitivity that may influence the choice
of drugs for each patient, and allow the
unnecessary treatment of patients with
unresponsive tumours to be avoided.
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